GlassScriptPhysician profile
John A Gschwend
NPI 1386691582
$1,706.68
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $522 · 2021: $528 · 2022: $71.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.79 | 2019-2022 | |
| Therapeuticsmd, INC. | $147.59 | 2019-2022 | |
| Allergan, INC. | $140.51 | 2019-2020 | |
| Duchesnay USA Incorporated | $118.68 | 2019 | |
| Daiichi Sankyo INC. | $96.48 | 2019-2021 | |
| Pfizer INC. | $95.75 | 2019-2021 | |
| Avion Pharmaceuticals | $78.29 | 2019-2021 | |
| Coopersurgical, INC. | $75.43 | 2020-2021 | |
| Millicent US INC | $72.72 | 2019-2020 | |
| Agile Therapeutics, INC. | $70.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.37 | 2019-2021 | |
| Dysis Medical, INC. | $58.77 | 2020 | |
| Vertical Pharmaceuticals, LLC | $43.07 | 2019-2020 | |
| Hologic Sales and Service, LLC | $41.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $37.56 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $33.33 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $33.18 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $30.61 | 2021 | |
| Evofem Biosciences, INC. | $25.93 | 2021 | |
| Astellas Pharma US INC | $23.16 | 2020 | |
| Mayne Pharma Commercial LLC | $20.37 | 2021 | |
| Exeltis, USA INC. | $17.52 | 2019 | |
| Organon LLC | $16.10 | 2021 | |
| Tactile Systems Technology INC | $13.79 | 2019 | |
| Zyla Life Sciences, INC. | $12.68 | 2020 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gschwend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.